Table 1 Patients’ characteristics in different groups (EBER cut-off: 20%).

From: Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age

Variable

Number. (%)

All patients (N = 250)

P value

Elderly group

P value

Young group

P value

EBV+

EBV−

EBV+

EBV−

EBV+

EBV−

Number. (%)

Number. (%)

Number. (%)

Age

250

35

215

 

25

141

 

10

74

 

≥50y

166 (66.4)

25 (71.4)

141 (65.6)

0.497

25

141

NA

NA

NA

NA

<50y

84 (33.6)

10 (28.6)

74 (34.4)

 

NA

NA

 

10

74

 

Sex

250

35

215

 

25

141

 

10

74

 

Male

144 (57.6)

27 (77.1)

117 (54.4)

0.012

19 (76.0)

76 (53.9)

0.040

8 (80.0)

41 (55.4)

0.182

Female

106 (42.4)

8 (22.9)

98 (45.6)

 

6 (24.0)

65 (46.1)

 

2 (20.0)

33 (45.6)

 

Site

250

35

215

 

25

141

 

10

74

 

Extranodal

106 (41.6)

20 (57.1)

86 (40.0)

0.057

15 (60.0)

62 (44.0)

0.139

5 (50.0)

24 (32.4)

0.303

Lymph node

144 (58.4)

15 (42.9)

129 (60.0)

 

10 (40.0)

79 (56.0)

 

5 (50.0)

50 (67.6)

 

Stage

250

35

215

 

25

141

 

10

74

 

I/II

125 (50.0)

12 (34.3)

113 (52.6)

0.045

8 (32.0)

68 (48.2)

0.133

4 (40.0)

45 (60.8)

0.307

III/IV

125 (50.0)

23 (65.7)

102 (47.4)

 

17 (68.0)

73 (51.8)

 

6 (60.0)

29 (39.2)

 

ECOG PS

238

25

213

 

15

144

 

10

69

 

0–1

207 (83.5)

16 (64.0)

191 (89.7)

0.002

9 (60.0)

126 (87.5)

0.013

7 (70.0)

65 (94.2)

0.040

2–4

31 (16.5)

9 (36.0)

22 (10.3)

 

6 (40.0)

18 (12.5)

 

3 (30.0)

4 (5.8)

 

ESI

242

30

212

 

20

139

 

10

73

 

0–1

194 (80.2)

20 (66.7)

174 (82.1)

0.048

13 (65.0)

112 (80.6)

0.143

7 (70.0)

62 (84.9)

0.361

>1

48 (19.8)

10 (33.3)

38 (17.9)

 

7 (35.0)

27 (19.4)

 

3 (30.0)

11 (15.1)

 

IPI

237

29

208

 

19

139

 

10

69

 

0–2

174 (73.4)

17 (58.6)

157 (75.5)

0.054

9 (47.4)

93 (66.9)

0.095

8 (80.0)

64 (92.8)

0.214

3–5

63 (26.6)

12 (41.4)

51 (24.5)

 

10 (52.6)

46 (33.1)

 

2 (20.0)

5 (7.2)

 

Treatment

250

35

215

 

25

141

 

10

74

 

R-CHOP

125 (50.0)

27 (77.1)

98 (45.6)

NA

19 (76.0)

58 (41.1)

NA

8 (80.0)

40 (54.1)

NA

R-DA- EPOCH

35 (14.0)

7 (20.0)

28 (13.0)

NA

5 (20.0)

23 (16.3)

NA

2 (20.0)

5 (6.8)

NA

CHOP

90 (36.0)

1 (2.9)

89 (41.4)

NA

1 (4.0)

60 (42.6)

NA

0 (0.0)

29 (39.1)

NA

Response

250

35

215

 

25

141

 

10

74

 

CR(u)/PR

212 (84.8)

23 (65.7)

189 (87.9)

0.001

16 (64.0)

119 (84.4)

0.025

7 (70.0)

70 (94.6)

0.034

No response

38 (15.2)

12 (34.3)

26 (12.1)

 

9 (36.0)

22 (15.6)

 

3 (30.0)

4 (5.4)

 
  1. Abbreviations: EBV: Epstein-Barr virus; ESI: extranodal sites involvement; ECOG PS: Eastern Cooperative Oncology Group Performance Status; IPI: International Prognostic Index; NCCN: National Comprehensive Cancer Network; Chemo: R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-DA-EPOCH: Dose-adjusted EPOCH-R ([etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin] + rituximab); CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; chemotherapy; CR(u): complete remission(unconfirmed); PR: partial remission.
Back to article page